W. B. Mattes 1 , * , H. G. Kamp 2 , E. Fabian 2 , M. Herold 3 , G. Krennrich 2 , R. Looser 3 , W. Mellert 2 , A. Prokoudine 3 , V. Strauss 2 , B. van Ravenzwaay 2 , T. Walk 3 , H. Naraoka 4 , K. Omura 4 , I. Schuppe-Koistinen 5 , S. Nadanaciva 6 , E. D. Bush 7 , N. Moeller 8 , P. Ruiz-Noppinger 8 , S. P. Piccoli 9
21 May 2013
Addressing safety concerns such as drug-induced kidney injury (DIKI) early in the drug pharmaceutical development process ensures both patient safety and efficient clinical development. We describe a unique adjunct to standard safety assessment wherein the metabolite profile of treated animals is compared with the MetaMap Tox metabolomics database in order to predict the potential for a wide variety of adverse events, including DIKI. To examine this approach, a study of five compounds (phenytoin, cyclosporin A, doxorubicin, captopril, and lisinopril) was initiated by the Technology Evaluation Consortium under the auspices of the Drug Safety Executive Council (DSEC). The metabolite profiles for rats treated with these compounds matched established reference patterns in the MetaMap Tox metabolomics database indicative of each compound's well-described clinical toxicities. For example, the DIKI associated with cyclosporine A and doxorubicin was correctly predicted by metabolite profiling, while no evidence for DIKI was found for phenytoin, consistent with its clinical picture. In some cases the clinical toxicity (hepatotoxicity), not generally seen in animal studies, was detected with MetaMap Tox. Thus metabolite profiling coupled with the MetaMap Tox metabolomics database offers a unique and powerful approach for augmenting safety assessment and avoiding clinical adverse events such as DIKI.